AZ and Innate to collaborate in immuno-oncology
ASTRAZENECA AND Innate Pharma ANNOUNCE GLOBAL CO-DEVELOPMENT AND COMMERCIALISATION COLLABORATION FOR iph2201 IN IMMUNO-ONCOLOGY AstraZeneca and MedImmune, the Company's global biologics research and development arm, today announced that they have entered into a collaboration to accelerate and broaden the development of Innate Pharma SA's proprietary anti-NKG2A antibody, IPH2201, including in combination with MEDI4736, an anti-PD-L1 immune checkpoint inhibitor developed by MedImmune. Currently in Phase II development, IPH2201 is a potential first-in-class humanised IgG4 antibody. NKG2A